ESMO 2026: Sacituzumab Govitecan (SG) Combined with Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results from Phase 1b TROPHY-U-01 Cohort 7
(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held in Madrid, Spain, was host to the…